Oregon State University Captures Live Chemistry Driving Alzheimer’s Disease Progression

The Groundbreaking Discovery at Oregon State University

Oregon State University researchers have achieved a pivotal advancement in Alzheimer's disease research by developing a technique to observe, in real time, the chemical interactions that drive the disease's progression. Led by Associate Professor Marilyn Rampersad Mackiewicz in the Department of Chemistry, the team utilized fluorescence anisotropy—a sensitive optical method that measures the rotational mobility of fluorescently labeled molecules—to monitor how metal ions, particularly copper (Cu²⁺), accelerate the aggregation of amyloid-beta (Aβ) proteins. These protein clumps are hallmarks of Alzheimer's, disrupting neural communication and contributing to cognitive decline.80

This work not only visualizes the aggregation process second by second but also demonstrates how specific chelators can selectively reverse it, offering hope for targeted therapies. The study, published in ACS Omega, highlights the role of undergraduate students in high-impact science, underscoring OSU's commitment to hands-on training through programs like SURE Science.81

Alzheimer's disease, the most common form of dementia, affects over 7.2 million Americans aged 65 and older in 2025, with projections nearing 13 million by 2050. It ranks as the sixth leading cause of death for those over 65, with deaths more than doubling since 2000.135

Understanding Amyloid-Beta Pathology in Alzheimer's

Amyloid-beta (Aβ), a peptide derived from the amyloid precursor protein, forms insoluble plaques in the brain that characterize Alzheimer's disease (AD). These plaques, along with neurofibrillary tangles from tau protein, lead to neuronal death and synaptic loss. Metal dyshomeostasis—imbalances in ions like copper, iron, and zinc—exacerbates Aβ aggregation, generating reactive oxygen species (ROS) that cause oxidative stress and inflammation.108

Copper, in particular, binds Aβ with high affinity, catalyzing its misfolding into toxic oligomers and fibrils. Prior studies showed elevated brain copper in AD patients, but lacked dynamic insights. OSU's approach addresses this by tracking live interactions, revealing Cu²⁺ as the strongest aggregator compared to Fe³⁺ (moderate) and Zn²⁺ (minimal).81

Fluorescence Anisotropy: The Key Technique

Fluorescence anisotropy measures the depolarization of emitted light from a fluorophore (here, TAMRA-labeled Aβ_1-42) as it rotates in solution. Monomeric proteins tumble freely (low anisotropy), while aggregates rotate slowly (high anisotropy). The OSU team excited samples at 545 nm, monitoring emission at 600 nm in real time, achieving high sensitivity without invasive probes.

• Incubation with metals (33-65 μM) for 10 minutes induced dose- and pH-dependent (6.5-8.0) aggregation.
• Chelator addition (EDTA 2.5 mM or Ni-bme-dach 0.35 mM) quantified reversal kinetics.
• Δr (change in anisotropy) provided quantitative aggregation metrics.

This non-destructive method outperforms traditional endpoints like ThT fluorescence or SDS-PAGE, enabling kinetic studies.81

Copper's Pivotal Role Confirmed

Cu²⁺ triggered the largest anisotropy increase, forming nanoscale fibrils visible via TEM and AFM (heights up to 10 nm). UV-vis spectroscopy showed d-d transitions confirming Cu-Aβ coordination. This aligns with epidemiological data linking brain copper dysregulation to AD progression, where excess 'free' copper promotes Aβ oligomerization.110

Chelator Showdown: Selective vs. Non-Selective

Ni-bme-dach's selectivity avoids depleting essential metals like Zn²⁺, crucial for synaptic function. This could minimize off-target effects in therapies.81 For full paper details, see the ACS Omega publication.

Photo by Porter Raab on Unsplash

Undergraduate Research: Fueling Innovation

A hallmark of the study is heavy undergrad involvement—Alyssa Schroeder (OSU) and four from Portland State. Supported by OSU's SURE Science Program, which provides scholarships for summer research, this exemplifies how US universities train the next generation. Mackiewicz's lab, focused on nanomaterials for AD and cancer, emphasizes inclusive mentorship.132

Validation Through Advanced Imaging

TEM revealed Cu-Aβ fibrils (lengths 100-500 nm); Ni-bme-dach reduced them to amorphous deposits. AFM quantified height reductions from 8-10 nm aggregates to <2 nm monomers. These multimodal confirmations bolster the anisotropy data's reliability.

Implications for Alzheimer's Therapies

Current anti-Aβ drugs like lecanemab reduce plaques but show modest cognitive benefits, partly due to incomplete aggregation understanding. Selective Cu chelation could complement them, targeting metal-driven toxicity. While preclinical, this roadmap addresses why broad chelators fail clinically. Learn more via OSU's news release.102

OSU's Leadership in Neurodegenerative Research

OSU's College of Science invests in such work via SURE and donor funding, positioning it as a hub for bionanomaterials. Mackiewicz's awards highlight excellence in teaching and equity. This aligns with national efforts, amid $384 billion annual AD costs.135

Challenges and Future Directions

• Scale to cellular/animal models for bioavailability.
• Test Ni-bme-dach in vivo Cu-Aβ dynamics.
• Explore other metals/chelators.
• Clinical translation: 5-10 years away.

Broader context: Copper's role debated, but OSU data supports targeted chelation amid rising AD burden.

Photo by Casey Olsen on Unsplash

Career Opportunities in AD Research

US universities like OSU seek chemists, biologists for neurodegeneration. Postdocs, faculty roles abound in protein dynamics, nanomedicine.